|
|
Murapalmitine |
|
Vaxjo ID |
65 |
|
Vaccine Adjuvant Name |
Murapalmitine |
|
Alternative Names |
Nac-Mur-L-Thr-D-isoGIn-sn-glyceroI dipalmitoyl |
|
Adjuvant VO ID |
VO_0001304
|
|
Description |
Administered in water-in-oil (w/o) emulsion as adjuvant of humoral and cell-mediated responses (Vogel and Powell, 1995). |
|
Stage of Development |
Clinical Trial |
|
Components |
Nac-Mur-L-Thr-D-isoGIn-sn-glyceroI dipalmitoyl (Vogel and Powell, 1995). |
|
Molecular Weight |
1072 |
|
Appearance |
White powder |
|
Storage |
Stored as a powder at 4°C. Protect from light and humidity (Vogel and Powell, 1995). |
|
Function |
Lipophilic MDPs are more active than hydrophilic MDPs. In saline, they are strong immunoadjuvants of humoral immunity and weaker adjuvants of cell-mediated immunity. In 50% w/o emulsions, they are strong immunoadjuvants and mimics Freund's complete activity. In contrast with other molecules of this subgroup, Murapalmitine is devoid of side effects and thus has been chosen for further development (Vogel and Powell, 1995). |
|
Safety |
Acute toxicity in mice, rats, rabbits and guinea pigs satisfactorily completed. Preliminary subacute toxicity in dogs satisfactorily completed. Further toxicology studies in process (Vogel and Powell, 1995). |
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
|
